BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34561270)

  • 41. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
    Wu A; Maxwell R; Xia Y; Cardarelli P; Oyasu M; Belcaid Z; Kim E; Hung A; Luksik AS; Garzon-Muvdi T; Jackson CM; Mathios D; Theodros D; Cogswell J; Brem H; Pardoll DM; Lim M
    J Neurooncol; 2019 Jun; 143(2):241-249. PubMed ID: 31025274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human gamma-delta (γδ) T cell therapy for glioblastoma: A novel alternative to overcome challenges of adoptive immune cell therapy.
    Choi H; Kim TG; Jeun SS; Ahn S
    Cancer Lett; 2023 Sep; 571():216335. PubMed ID: 37544475
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biomarkers for immunotherapy for treatment of glioblastoma.
    Lynes JP; Nwankwo AK; Sur HP; Sanchez VE; Sarpong KA; Ariyo OI; Dominah GA; Nduom EK
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474411
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in research on immune escape mechanism of glioma.
    Guo X; Wang G
    CNS Neurosci Ther; 2023 Jul; 29(7):1709-1720. PubMed ID: 37088950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma.
    Lucca LE; Hafler DA
    Immunol Rev; 2017 Mar; 276(1):9-25. PubMed ID: 28258696
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunotherapy of glioblastoma: Recent advances and future prospects.
    Yuan B; Wang G; Tang X; Tong A; Zhou L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
    Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
    Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor.
    Hotchkiss KM; Sampson JH
    J Neurooncol; 2021 Jan; 151(1):55-62. PubMed ID: 32813186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy for Neuro-oncology.
    Majd NK; Dasgupta PR; de Groot JF
    Adv Exp Med Biol; 2021; 1342():233-258. PubMed ID: 34972967
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Advances in Immunotherapies for Gliomas.
    Zhang M; Choi J; Lim M
    Curr Neurol Neurosci Rep; 2022 Jan; 22(1):1-10. PubMed ID: 35107784
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.
    Habashy KJ; Mansour R; Moussalem C; Sawaya R; Massaad MJ
    Br J Cancer; 2022 Oct; 127(6):976-987. PubMed ID: 35662275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perspectives on Microglia-Based Immune Therapies Against Glioblastoma.
    Rivera M; Bander ED; Cisse B
    World Neurosurg; 2021 Oct; 154():228-231. PubMed ID: 34583500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment.
    Kwok D; Okada H
    J Neurooncol; 2020 Apr; 147(2):281-295. PubMed ID: 32185647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Developing immunotherapeutic strategies to target brain tumors.
    Lieberman NA; Moyes KW; Crane CA
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):775-88. PubMed ID: 27253692
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance.
    Noch EK; Ramakrishna R; Magge R
    World Neurosurg; 2018 Aug; 116():505-517. PubMed ID: 30049045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.